| |
Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, announces that it has more than doubled the number of new clients using its strategic services during the first six months of 2011.
Since its spin-out from the University of Nottingham in August 2010, the company has enjoyed increasing success. Additionally, PRECOS has added a new senior member of staff to its rapidly growing team in order to accommodate this growth and the significant expansion envisaged for 2012.
Dr. Aaron Cranston joins PRECOS as head of in vivo services with 15 years’ extensive experience in oncology research. His expertise has been honed in both academia and practice, more recently in drug discovery and translational medicine for KuDOS Pharmaceuticals as Head of Pharmacology.
In line with the company’s continued projected growth, PRECOS is also doubling its existing laboratory space by mid 2012. The simultaneous expansion of staffing, client base and operational facilities at PRECOS will support the growth of its leading in vitro and in vivo oncology drug discovery services.
“I am delighted to be joining the PRECOS team and participating in the leading specialist services that PRECOS provides,” comments Dr. Cranston. “The company is an innovative leader in oncology and is committed to offering a world-class service to its clients. I am looking forward to being able to apply my experience and expertise to existing and new projects.”
Dr Neil Rotherham, chairman of PRECOS comments,“Aaron’s extensive background in the drug discovery field makes him an ideal addition to our growing team and we look forward to benefiting from his expertise. We are taking significant steps in our growth strategy by providing services for an ever-expanding number of clients. Aaron’s appointment will strengthen our senior team in support of our growing client base and we aim to continue expanding into 2012 and beyond.”
The technology used by PRECOS offers several unique methods which allow drugs to be screened early in the research process for anti-cancer activity, while those with no useful activity can be ignored. It is possible to create cell lines from patient primary tissue that “never see plastic” and are therefore not selected based on their ability to survive in vitro, but on their true characteristics as cancer cells. PRECOS can deliver a customised screening platform either in 3-D in vitro and/or in vivo that can far more closely model the development of cancer and therefore more accurately reflect the effect of potential candidate entities.
For further information on PRECOS, please call +44 (0)870 166 6234, email enquiries[.]precos.co.uk or visit the website.
|
pr[.]scottpr.com 
